Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904123 · ClinicalTrials.gov registry record · Phase 1
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
A Phase 1 study of Metastatic Melanoma and Recurrent Glioblastoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT01904123: Completed Phase 1 study of Metastatic Melanoma and Recurrent Glioblastoma, sponsored by M.D. Anderson Cancer Center.
NCT01904123 is a Phase 1 study of Metastatic Melanoma and Recurrent Glioblastoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01904123, a Phase 1 study of Metastatic Melanoma and Recurrent Glioblastoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting worse. STAT3 inhibitor WP1066 may stop the growth of tumor cells and modulate the immune system.
Primary Outcome
A DLT will be defined as an adverse event or an abnormal laboratory value assessed as being at least possibly related to the investigation agent that occurs during the first 28 days after administration of the first dose of JAK2 inhibitor WP1066 and will be assigned a grade based on National Cancer Institute (NCI) Common Terminology Criteria (CTC). Any grade toxicity at least possibly related to WP1066 that leads to dose delay of \>= 2 weeks will be considered a DLT.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG STAT3 Inhibitor WP1066
- OTHER Pharmacological Study
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 1 |
What the finished NCT01904123 record still lists
NCT01904123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (90% lower).
The record links to 5 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01904123 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01904123 about?
NCT01904123 is a clinical study titled "STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain". This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting worse. STAT3 inhibitor WP1066 may stop the growth of tumor cells and modula...
What is the current status of trial NCT01904123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-07-13. Estimated completion is 2022-03-16.
What conditions does trial NCT01904123 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Recurrent Glioblastoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Glioma, Recurrent Brain Neoplasm.
What interventions are being tested in trial NCT01904123?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), STAT3 Inhibitor WP1066 (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01904123?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01904123 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01904123's enrollment target sits among peer trials
8 90th of 91 higher than 2 of 91 other Metastatic Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI